Advertising in a prestigious medical magazine shows that the use of the drug Ramidsibir, given to the Israeli minibus driver who was in serious condition and recovering, may be effective against the corona virus

• Ampoules of the anti-viral drug "Ramidsibir" // Photo: Reuters

Encouraging results for experimental treatment of Corona: Two-thirds of patients, most of them breathing or with the complications, who have been given Gilead's antiviral drug Ramadsibir - have improved their condition. This is evidenced by information gathered under compassionate care, a last-line drug treatment that is not outlined for severely ill patients, given to 53 inpatients with complications who received treatment. The article was published in the prestigious New England Medical Journal (NEJM) Medical Journal.

Remedisibir is an antiviral drug, which shortens the length of time the virus replicates in the body, by the Gilad Pharmaceutical Company, which operates on the corona virus replication mechanism. It has been shown to be effective in laboratory conditions on other Corona-SARS and MERS family viruses and therefore has high expectations.

In the country of medicine, compassionate treatment was given to about 3-4 patients, one of whom is the driver of the tour bus (38) the first serious patient to be admitted to Poriya Hospital, recovered and released. However, in recent weeks due to increasing demand around the world, Israeli specialist doctors say that the drug cannot be ordered for patients.

The study found that 18 days later, 68% of patients had improved respiratory metrics (36 of 53). It was also found that more than half of the patients who were breathing were weaned from the respirator (17 out of 30) and nearly half of all patients were discharged from the hospital. Seven patients died during the study period. (The proportion of people who died was higher than the number of patients who were breathing and 70 years of age or older). Thirty-four of the study participants were respirators, of which 4 were connected to ACMO (a device that replaces heart and lung activity).

After 28 days of follow-up, it was found that 84% of patients were discharged from a hospital or had improved their respiratory condition.

"There is currently no proven treatment for covid-19. We cannot draw any definitive conclusions from the information collected but the impressions from the hospitalized group that received a hopeful Ramadsibir," says Dr. Jonathan Green, lead researcher, from Cedars Sinai Hospital in Los Angeles. Les "We expect to see results of controlled research that may be valid for our findings."

The study did not include a control group and had not yet been peer-reviewed. Therefore, it is not possible at this stage to assess what the results would be without treatment with Ramadsibir. Ramadsibir is still a research drug that is not listed anywhere in the world. Therefore, there are currently 7 large-scale, third-phase, simultaneous studies in various parts of the world to determine the efficacy and safety of Ramadsibir, in accordance with the accepted scientific research rules.